Use of drugs in the primary prevention of arterial hypertension and dyslipidemia;Prevención primaria farmacológica en hipertensión arterial y dislipemias

Revista Espanola de Cardiologia

Volumn 61, Issue 8, 2008, Pages 861-879

  González Juanatey, José R ^a,b   Ramos, Pilar Mazón ^a,b  

^a University Hospital of Santiago de Compostela   (Spain)

^b NONE   (Spain)

Author keywords

Arterial hypertension; Drugs; Dyslipidemia; Primary prevention of cardiovascular disease

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; ATORVASTATIN; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORTALIDONE; CLONIDINE; DOXAZOSIN; EPROSARTAN; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; LISINOPRIL; LOSARTAN; LOW DENSITY LIPOPROTEIN; PERINDOPRIL; PLACEBO; RAMIPRIL; RESERPINE; TELMISARTAN; VALSARTAN; ANTILIPEMIC AGENT;

ARTERIAL PRESSURE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; DYSLIPIDEMIA; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; KIDNEY DISEASE; LIFESTYLE MODIFICATION; LIPOPROTEIN BLOOD LEVEL; PRIMARY PREVENTION; PROGNOSIS; REVASCULARIZATION; REVIEW; RISK REDUCTION; ARTICLE; CHEMOPROPHYLAXIS; DRUG COMBINATION; PRACTICE GUIDELINE; RISK FACTOR;

ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CHEMOPREVENTION; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; RISK FACTORS;

EID: 49449112125     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1157/13124997     Document Type: Article

References (57)

1. Medrano MJ, Pastor-Barriuso R, Boix R, Del Barrio JL, Damián J, Álvarez R, et al, investigadores del estudio ZACARIS. Riesgo de enfermedad coronaria atribuible a factores de riesgo cardiovascular en la población española. Rev Esp Cardiol. 2007;60:1250-6.
2. Sans S, Fitzgerald AP, Royo D, Conroy R, Graham I. Callbración del SCORE de riesgo cardiovascular para su utilización en España. Rev Esp Cardiol. 2007;60:476-85.
3. Mancia G, De Baker G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. Guías de práctica clínica para el tratamiento de la hipertensión arterial. Rev Esp Cardiol. 2007;60:968e1-e94.
4. Marrugat JR, Subirana I, Comín E, Cabezas C, Vila J, Elosua R, et al. Validity of an adaptation of the Framingham cardiovascular risk function: the VERIFICA Study. J Epidemiol Community Health. 2007;61:40-7.
5. Mazón P, Bertomeu V, Palma JL, Quiles J, Guindo J, González-Juanatey JR. Tratamiento global del riesgo cardiovascular en el paciente hipertenso. Temas de actualidad 2006. Rev Esp Cadiol. 2007;60 Supl 1:79-91.
6. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;32:1427.
7. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, et al; for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med. 1993;328:914-21.
8. Rosengren A, Wilhelmsen L, Hagman M, Wedel H. Natural history of myocardial infarction and angina pectoris in a general population sample of middle aged men: a 16-year follow-up of the Primary Prevention Study, Goteborg, Sweden. J Intern Med. 1998;244:495-505.
9. Doyle AE. The Australian National Blood Pressure Study. Aust Fam Physician. 1981;10:558-9.
10. Kostis JB, Davis BR, Cutler J, Grimm RH Jr, Berge KG, Cohen JD, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA. 1997;278:212-6.
11. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350:757-64.
12. Peart WS, Miall WE. MRC treatment trial for mild hypertension. Br Med J. 1977;2:1023.
13. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022-31.
14. Blood Pressure Lowering Treatment Trilaists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165:1410-9.
15. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755-62.
16. Zanchetti A. Evidence-based medicine in hypertension: what type of evidence? J Hypertens. 2005;23:1113-20.
17. Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens. 2005;23:1113-20.
18. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355:253-9.
19. MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829-40.
20. Villarosa IP, Bakris GL. The Appropriate Blood Pressure Control in Diabetes (ABCD) Trial. J Hum Hypertens. 1998;12:653-5.
21. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al; INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805-16.
22. The ONTARGET investigators. Telmisartan, ramipril or both in patients at high risk of vascular events. N Engl J Med. 2008;358:1547-59.
23. Staessen JA, Li Y, Richard T. Oral renin inhibitors. Lancet. 2006;368:1449-56.
24. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibition or calcium channel blocker vs diuretic: The Anthypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. JAMA. 2002;288:2981-97.
25. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-52.
26. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosine vs chlorthalidone: The Anthypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. JAMA. 2000;283:1967-75.
27. Mancia G. Role of outcome trials in providing information on antihypertensive treatment: importance and limitations. Am J Hypertens. 2006;19:1-7.
28. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, De Faire U, Fyrquist F, et al. Cardiovascular mortality and morbidity in the Losartan Intervention for Endpoint Reduction in hpertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
29. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendoflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA). A multicentre randomized controlled trial. Lancet. 2005;366:895-906.
30. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. Differencial impact of blood pressure - lowering drugs on central aortic pressure and clinical outcomes: principal results of the conduit artery function evaluation, CAFÉ study. Circulation. 2006;113:1213-25.
31. Hypertension: management of hypertension in adults in primary care. NICE/BHS; 2006. Disponible en: www.nice.org.uk/CG034.GL
32. Sever PR, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. ASCOT investigators. The prevention of coronary events and stroke with atorvastatin in hypertensive subjects with average or below average cholesterol levels. The Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT-LLA). Lancet. 2003;361:1149-58.
33. Jamerson KA, Bakris GL, Wun CC, Dahlof B, Lefkowitz M, Manfreda S, et al. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to comparethe clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens. 2004;17:793-801.
34. Boulanger JM, Schradader JM, Lüders S, Kulschewski A, Hammersen F, Plate K, et al. Morbidity and mortality alter stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005;36:1218-26.
35. Mochizuki S, Dahlöf B, Shimizu M, Ikewaki K, Yoshikawa M, Tamiguchi I, et al. Valsartan in a Japanese population with hypertensionand other cardiovascular disease (JIKEI-HEARTstudy). A randomized open-label blinded endpoint morbidity-mortality study. Lancet. 2007;369:1431-9.
36. Gueyffier F, Bulpitt C, Boissel JP, Schron E, Ekbom T, Fagard R, et al. Antyhipertensive drugs in very old people: a subgroup analysis of randomised controlled trials. Lancet. 1999;353:793-6.
37. Bulpitt CJ, Beckett NS, Cooke J, Dumitrascu DL, Gil-Extremera B, Nachev C, et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens. 2003;21:2409-17.
38. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887-98.
39. Elliot WJ, Meyer PM. Incident diabetes in clinical trilas of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369:201-7.
40. Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobiqio R, Fillipuci L, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 2004;43:963-9.
41. Kitamura N, Takahashi Y, Yamadate S, Asai S. Angiotensin II receptor blockers decreased blood glucose levels: a longitudinal survey using data from electronic medical records. Cardiovasc Diabetol. 2007;6:26.
42. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45:1832-9.
43. Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, Aurup P, et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45:705-11.
44. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005;366:2026-33.
45. Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy and safety of cholesterol-loweing treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-78.
46. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burel Gl, Cifkova R, et al. Guías de práctica clínica sobre prevención de la enfermedad cardiovascular. Rev Esp Cardiol. 2008;61:82.e1-e49.
47. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-39.
48. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein KJ, Komajda M, Lopez-Sendon JL et al. Effects of Torcetrapib in Patients at High Risk for Coronary Events. N Engl J Med. 2007;357:2109-22.
49. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, et al. Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370:1829-39.
50. Thavendiranathan P, Bagai A, Brookhart MA, Choudry NK. Primary prevention of cardiovascular diseases with statin therapy. Arch Intern Med. 2006;166:2307-13.
51. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431-43.
52. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol. 2005;46:1855-62.
53. Tenkanen L, Mänttäri M, Kovanen PT, Virkkunen H, Manninen V. Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. Arch Intern Med. 2006;166:743-8.
54. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849-61.
55. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004; 364:685-96.
56. Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363:757-67.
57. Howard BV, Roman MJ, Devereux RB, Fleg JL, Galloway JM, Henderson JA, et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA. 2008;299:1678-89.